Study to Investigate Effect of Sildenafil on Clitoral Engorgement as Measured by Magnetic Resonance Imaging (MRI) in Pre-menopausal Women With Female Sexual Arousal Disorder
Completed · Phase 2 · Has a placebo group
Conditions studied: Female Sexual Arousal Disorder
In brief
The purpose of this study is to investigate the effect of 100 mg sildenafil on clitoral engorgement in pre-menopausal women, as well as examining the safety and toleration of the drug.
Key facts
- Study ID
- NCT00640458
- Run by
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- People needed
- 20
- Starts
- 2004-04-01
- Expected to finish
- 2007-03-01
- Last updated by the study team
- 2021-02-01
Who can join
Age: 18 and older, up to 45. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Pre-menopausal women aged 18-45 with a primary diagnosis of Female Sexual Arousal Disorder for at least 6 months prior to entering the study. The FSAD could have been associated with female orgasmic disorder (FOD) and/or superficial or introital dyspareunia.
You may not qualify if…
- Subjects with hypoactive sexual desire disorder.
- Subjects not using an acceptable mean of contraception for the duration of the study.
- Subjects who were prescribed and/or taking medication which were contraindicated or cautioned with concomitant intake of sildenafil.
Where it is running
- Pfizer Investigational Site — Seattle, Washington, United States
- Pfizer Investigational Site — Seattle, Washington, United States
- Pfizer Investigational Site — Nedlands, Western Australia, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.